Effects of SZV-2649, a new multiple ion channel inhibitor mexiletine analogue.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
05 Oct 2024
05 Oct 2024
Historique:
received:
13
06
2024
accepted:
18
09
2024
medline:
6
10
2024
pubmed:
6
10
2024
entrez:
5
10
2024
Statut:
epublish
Résumé
The antiarrhythmic and cardiac electrophysiological effects of SZV-2649 that contains a 2,6-diiodophenoxy moiety but lacks the benzofuran ring system present in amiodarone, were studied in mammalian cell line, rat and dog cardiac preparations. SZV-2649 exerted antiarrhythmic effects against coronary artery occlusion/reperfusion induced ventricular arrhythmias in rats and in acetylcholine- and burst stimulation induced atrial fibrillation in dogs. SZV-2649 inhibited hERG and GIRK currents in HEK cells (IC
Identifiants
pubmed: 39369049
doi: 10.1038/s41598-024-73576-5
pii: 10.1038/s41598-024-73576-5
doi:
Substances chimiques
Anti-Arrhythmia Agents
0
Mexiletine
1U511HHV4Z
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
23188Subventions
Organisme : Ministry of Human Capacities Hungary
ID : EFOP-3.6.2-16-2017-00006, the UNKP for young researchers, UNKP-23-5-SZTE-704
Organisme : Ministry of Human Capacities Hungary
ID : EFOP-3.6.2-16-2017-00006, the UNKP for young researchers, UNKP-23-5-SZTE-704
Organisme : Ministry of Human Capacities Hungary
ID : EFOP-3.6.2-16-2017-00006, the UNKP for young researchers, UNKP-23-5-SZTE-704
Organisme : Ministry of Human Capacities Hungary
ID : EFOP-3.6.2-16-2017-00006, the UNKP for young researchers, UNKP-23-5-SZTE-704
Organisme : Ministry of Human Capacities Hungary
ID : EFOP-3.6.2-16-2017-00006, the UNKP for young researchers, UNKP-23-5-SZTE-704
Organisme : Ministry of Human Capacities Hungary
ID : EFOP-3.6.2-16-2017-00006, the UNKP for young researchers, UNKP-23-5-SZTE-704
Organisme : Ministry of Human Capacities Hungary
ID : EFOP-3.6.2-16-2017-00006, the UNKP for young researchers, UNKP-23-5-SZTE-704
Organisme : Ministry of Human Capacities Hungary
ID : EFOP-3.6.2-16-2017-00006, the UNKP for young researchers, UNKP-23-5-SZTE-704
Organisme : Ministry of Human Capacities Hungary
ID : EFOP-3.6.2-16-2017-00006, the UNKP for young researchers, UNKP-23-5-SZTE-704
Organisme : Ministry for Innovation and Technology, Cooperative Doctoral Programme
ID : KDP-2020
Organisme : Recovery and Resilience Facility (RRF)
ID : RRF-2.3.1-21-2022-00001
Organisme : National Research Development and Innovation Office
ID : NKFIH K 135464, K 142738, K 147212 TKP2021-EGA-32, FK 138223, GINOP-2.3.2.-15-2016-00006, GINOP-2.3.2.-15-2016-00040
Organisme : National Research Development and Innovation Office
ID : NKFIH K 135464, K 142738, K 147212 TKP2021-EGA-32, FK 138223, GINOP-2.3.2.-15-2016-00006, GINOP-2.3.2.-15-2016-00040
Organisme : National Research Development and Innovation Office
ID : NKFIH K 135464, K 142738, K 147212 TKP2021-EGA-32, FK 138223, GINOP-2.3.2.-15-2016-00006, GINOP-2.3.2.-15-2016-00040
Organisme : National Research Development and Innovation Office
ID : NKFIH K 135464, K 142738, K 147212 TKP2021-EGA-32, FK 138223, GINOP-2.3.2.-15-2016-00006, GINOP-2.3.2.-15-2016-00040
Organisme : National Research Development and Innovation Office
ID : NKFIH K 135464, K 142738, K 147212 TKP2021-EGA-32, FK 138223, GINOP-2.3.2.-15-2016-00006, GINOP-2.3.2.-15-2016-00040
Organisme : National Research Development and Innovation Office
ID : NKFIH K 135464, K 142738, K 147212 TKP2021-EGA-32, FK 138223, GINOP-2.3.2.-15-2016-00006, GINOP-2.3.2.-15-2016-00040
Organisme : National Research Development and Innovation Office
ID : NKFIH K 135464, K 142738, K 147212 TKP2021-EGA-32, FK 138223, GINOP-2.3.2.-15-2016-00006, GINOP-2.3.2.-15-2016-00040
Organisme : The Albert Szent-Györgyi Medical School institutional grant
ID : SZTE AOK-KKA 2021, SZGYA 2021, SZTE AOK-KKA 2022
Organisme : The Albert Szent-Györgyi Medical School institutional grant
ID : SZTE AOK-KKA 2021, SZGYA 2021, SZTE AOK-KKA 2022
Organisme : The Albert Szent-Györgyi Medical School institutional grant
ID : SZTE AOK-KKA 2021, SZGYA 2021, SZTE AOK-KKA 2022
Organisme : Hungarian Research Network
ID : HUN-REN TKI project
Organisme : Hungarian Research Network
ID : HUN-REN TKI project
Organisme : Hungarian Research Network
ID : HUN-REN TKI project
Organisme : Hungarian Academy of Sciences, János Bolyai Research Scholarships
ID : bo_481_21
Organisme : National Heart Laboratory, Hungary
ID : RRF-2.3.1-21-2022-00003
Informations de copyright
© 2024. The Author(s).
Références
Tsao, C. W. et al. Heart Disease and Stroke Statistics—2022 update: a Report from the American Heart Association. Circulation. 145(8), e153–e639 (2022).
doi: 10.1161/CIR.0000000000001052
pubmed: 35078371
Kavousi, M. Differences in epidemiology and risk factors for Atrial Fibrillation between women and men. Front. Cardiovasc. Med.7, 3. https://doi.org/10.3389/fcvm.2020.00003 (2020).
doi: 10.3389/fcvm.2020.00003
pubmed: 32118043
pmcid: 7025483
Goldenberg, I. et al. Prior history of atrial fibrillation and arrhythmic outcomes: data from the WEARIT-II prospective registry. J. Cardiovasc. Electrophysiol.21 https://doi.org/10.1111/jce.16215 (2024 Feb). Online ahead of print.
Geng, M., Lin, A. & Nguyen, T. P. Revisiting Antiarrhythmic Drug Therapy for Atrial Fibrillation: Reviewing Lessons Learned and Redefining Therapeutic Paradigms. Front. Pharmacol. 11, 581837 doi: (2020). https://doi.org/10.3389/fphar.2020.581837 . eCollection 2020.
Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl. J. Med.321(6), 406–412. https://doi.org/10.1056/NEJM198908103210629 (1989).
doi: 10.1056/NEJM198908103210629
Siebels, J., Cappato, R., Rüppel, R., Schneider, M. A. & Kuck, K. H. Preliminary results of the Cardiac arrest study Hamburg (CASH). CASH investigators. Am. J. Cardiol.72(16), 109F–113F. https://doi.org/10.1016/0002-9149(93)90973-g (1993).
doi: 10.1016/0002-9149(93)90973-g
pubmed: 8237823
Waldo, A. L. et al. Survival with oral d-sotalol in patients with left ventricular dysfunction after myocardial infarction: rationale, design, and methods (the SWORD trial). Am. J. Cardiol.75(15), 1023–1027. https://doi.org/10.1016/s0002-9149(99)80717-6 (1995).
doi: 10.1016/s0002-9149(99)80717-6
pubmed: 7747682
Haugaard, M. M. et al. Pharmacologic inhibition of small-conductance calcium-activated potassium (SK) channels by NS8593 reveals atrial antiarrhythmic potential in horses. Heart Rhythm12(4), 825–835. https://doi.org/10.1016/j.hrthm.2014.12.028 (2015).
doi: 10.1016/j.hrthm.2014.12.028
pubmed: 25542425
Ford, J. et al. The positive frequency-dependent electrophysiological effects of the IKur inhibitor XEN-D0103 are desirable for the treatment of atrial fibrillation. Heart Rhythm13(2), 555–564. https://doi.org/10.1016/j.hrthm.2015.10.003 (2016).
doi: 10.1016/j.hrthm.2015.10.003
pubmed: 26455450
pmcid: 4768384
Ravens, U. & Wettwer, E. Ultra-rapid delayed rectifier channels: molecular basis and therapeutic implications. Cardiovasc. Res.89(4), 776–785. https://doi.org/10.1093/cvr/cvq398 (2011).
doi: 10.1093/cvr/cvq398
pubmed: 21159668
Liu, T. et al. Small-conductance calcium-activated potassium channels in the heart: expression, regulation and pathological implications. Philos. Trans. R Soc. Lond. B Biol. Sci.378(1879), 20220171. https://doi.org/10.1098/rstb.2022.0171 (2023).
doi: 10.1098/rstb.2022.0171
pubmed: 37122223
pmcid: 10150224
Feng, J., Wible, B., Li, G. R., Wang, Z. & Nattel, S. Antisense oligodeoxynucleotides directed against Kv1.5 mRNA specifically inhibit ultrarapid delayed rectifier K + current in cultured adult human atrial myocytes. Circ. Res.80(4), 572–579. https://doi.org/10.1161/01.res.80.4.572 (1997).
doi: 10.1161/01.res.80.4.572
pubmed: 9118489
Camm, A. J. et al. A randomized, double-blind, placebo-controlled trial assessing the efficacy of S66913 in patients with paroxysmal atrial fibrillation. Eur. Heart J. Cardiovasc. Pharmacother5(1), 21–28. https://doi.org/10.1093/ehjcvp/pvy022 (2019).
doi: 10.1093/ehjcvp/pvy022
pubmed: 30052825
Kudenchuk, P. J. et al. Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation. N Engl. J. Med.341(12), 871–878. https://doi.org/10.1056/NEJM199909163411203 (1999).
doi: 10.1056/NEJM199909163411203
pubmed: 10486418
Mujović, N., Dobrev, D., Marinković, M., Russo, V. & Potpara, T. S. The role of amiodarone in contemporary management of complex cardiac arrhythmias. Pharmacol. Res.151, 104521. https://doi.org/10.1016/j.phrs.2019.104521 (2020).
doi: 10.1016/j.phrs.2019.104521
pubmed: 31756386
Shinagawa, K., Shiroshita-Takeshita, A., Schram, G. & Nattel, S. Effects of antiarrhythmic drugs on fibrillation in the remodelled atrium: insights into the mechanism of the superior efficacy of amiodarone. Circulation. 107(10), 1440–1446. https://doi.org/10.1161/01.cir.0000055316.35552.74 (2003).
doi: 10.1161/01.cir.0000055316.35552.74
pubmed: 12642367
Ravens, U. Antiarrhythmic therapy in atrial fibrillation. Pharmacol. Ther.128(1), 129–145. https://doi.org/10.1016/j.pharmthera.2010.06.004 (2010).
doi: 10.1016/j.pharmthera.2010.06.004
pubmed: 20624425
Tisdale, J. E., Follin, S. L., Ordelova, A. & Webb, C. R. Risk factors for the development of specific noncardiovascular adverse effects associated with amiodarone. J. Clin. Pharmacol.35(4), 351–356. https://doi.org/10.1002/j.1552-4604.1995.tb04072.x (1995).
doi: 10.1002/j.1552-4604.1995.tb04072.x
pubmed: 7650222
Flanagan, R. J., Storey, G. C., Holt, D. W. & Farmer, P. B. Identification and measurement of desethylamiodarone in blood plasma specimens from amiodarone-treated patients. J. Pharm. Pharmacol.34(10), 638–643. https://doi.org/10.1111/j.2042-7158.1982.tb04692.x (1982).
doi: 10.1111/j.2042-7158.1982.tb04692.x
pubmed: 6128385
Nattel, S. Pharmacodynamic studies of Amiodarone and its active N-Desetyl metabolite. J. Cardiovasc. Pharmacol.8 (4), 771–777 (1986).
pubmed: 2427817
Kohajda, Z. et al. In vivo and cellular antiarrhythmic and cardiac electrophysiological effects of desethylamiodarone in dog cardiac preparations. Br. J. Pharmacol.179(13), 3382–3402. https://doi.org/10.1111/bph.15812 (2022).
doi: 10.1111/bph.15812
pubmed: 35106755
Varró, A. & Rabloczky, G. Antiarrhythmic effect of acute and chronic amiodarone treatment in conscious rats. J. Pharm. Pharmacol.38(10), 772–773. https://doi.org/10.1111/j.2042-7158.1986.tb04490.x (1986).
doi: 10.1111/j.2042-7158.1986.tb04490.x
pubmed: 2879002
Kodama, I., Kamiya, K., Toyama, J. & 20R-28R. Amiodarone: ionic and cellular mechanisms of action of the most promising class III agent. Am. J. Cardiol.84(9A). https://doi.org/10.1016/s0002-9149(99)00698-0 (1999).
Guillemare, E., Marion, A., Nisato, D. & Gautier, P. Inhibitory effects of dronedarone on muscarinic K + current in guinea pig atrial cells. J. Cardiovasc. Pharmacol.36(6), 802–805. https://doi.org/10.1097/00005344-200012000-00017 (2000).
doi: 10.1097/00005344-200012000-00017
pubmed: 11117382
Shi, R. O. et al. Long-term amiodarone treatment causes cardioselective hypothyroid-like alteration in gene expression profile. Eur. J. Pharmacol.578, 270–278. https://doi.org/10.1016/j.ejphar.2007.09.039 (2008).
doi: 10.1016/j.ejphar.2007.09.039
pubmed: 17991464
van Beeren, H. C., Bakker, O. & Wiersinga, W. M. Desthylamiodarone is a competitive inhibitor of the binding of thyroid hormone to the thyroid hormone alpha 1-receptor protein. Mol. Cell. Endocrinol.112, 15–19. https://doi.org/10.1016/0303-7207(95)03578-u (1995).
doi: 10.1016/0303-7207(95)03578-u
pubmed: 7589780
van Beeren, H. C., Bakker, O. & Wiereinga, W. M. Desethylamiodarone interferes with the binding of co-activator GRIP-1 to the beta 1-thyroid hormone receptor. FEBS Lett.481(3), 213–216. https://doi.org/10.1016/s0014-5793(00)01970-0 (2000).
doi: 10.1016/s0014-5793(00)01970-0
pubmed: 11007966
Latham, K. R., Sellitti, D. F. & Goldstein, R. E. Interaction of amiodarone and desethylamiodarone with solubilized nuclear thyroid hormone receptors. J. Am. Coll. Cardiol.9(4), 872–876. https://doi.org/10.1016/s0735-1097(87)80244-9 (1987).
doi: 10.1016/s0735-1097(87)80244-9
pubmed: 3558985
Taranto, V., Shvartsbeyn, M., Meehan, S. A. & Siegel, L. J. Dronedarone-induced phototoxic dermatitis. Int. J. Dermatol.62 (12), 1553–1554. https://doi.org/10.1111/ijd.16845 (2023).
doi: 10.1111/ijd.16845
pubmed: 37700581
Tave, A. et al. Risk of interstitial lung disease in patients treated for atrial fibrillation with dronedarone versus other antiarrhythmics. Pharmacoepidemiol Drug Saf.30(10), 1353–1359. https://doi.org/10.1002/pds.5233 (2021).
doi: 10.1002/pds.5233
pubmed: 33730412
pmcid: 8453764
Boriani, G. et al. Safety and efficacy of dronedarone from clinical trials to real-world evidence: implications for its use in atrial fibrillation. Europace. 21(12), 1764–1775. https://doi.org/10.1093/europace/euz193 (2019).
doi: 10.1093/europace/euz193
pubmed: 31324921
Matyus, P. et al. Development of pharmacophores for inhibitors of the rapid component of the cardiac delayed rectifier potassium current. Int. J. Quantum Chem.69, 21–30 (1998).
doi: 10.1002/(SICI)1097-461X(1998)69:1<21::AID-QUA4>3.0.CO;2-Z
Kovesdi, I. et al. Application of neural networks in structure- activity relationships. Med. Res. Rev.3, 249–269 (1999).
doi: 10.1002/(SICI)1098-1128(199905)19:3<249::AID-MED4>3.0.CO;2-0
Borosy, A., Keseru, K., Matyus, P. & Penzes I. 3D QSAR study of class I antiarrhythmics. J. Mol. Struct. (Theochem). 503, 113–129 (2000).
doi: 10.1016/S0166-1280(99)00367-X
Matyus, P., Rettegi, T., Varro, A. & Papp, J. G. New antiarrhythmic agents: a conceptually novel approach. Med. Res. Rev.20(4), 294–303 (2000).
doi: 10.1002/1098-1128(200007)20:4<294::AID-MED2>3.0.CO;2-5
pubmed: 10861728
Aminoalkylated benzoxy compounds. For use in the Treatment of Cardiac Disorders. P2300429/10.
Varro, A., Nakaya, Y., Elharrar, V. & Surawicz, B. Use-dependent effects of amiodarone on Vmax in cardiac Purkinje and ventricular muscle fibers. Eur. J. Pharmacol.112(3), 419–422. https://doi.org/10.1016/0014-2999(85)90791-5 (1985).
doi: 10.1016/0014-2999(85)90791-5
pubmed: 4018143
Varró, A. et al. Electrophysiological effects of dronedarone (SR 33589), a noniodinated amiodarone derivative in the canine heart: comparison with amiodarone. Br. J. Pharmacol.133(5), 625–634. https://doi.org/10.1038/sj.bjp.0704106 (2001).
doi: 10.1038/sj.bjp.0704106
pubmed: 11429385
pmcid: 1572824
Bigger, J. T. Jr. & Sahar, D. I. Clinical types of proarrhythmic response to antiarrhythmic drugs. Am. J. Cardiol.59(11). https://doi.org/10.1016/0002-9149(87)90195-0 (1987). 2E-9E.
Wang, F., Zhou, B., Sun, H. & Wu, X. Proarrhythmia associated with antiarrhythmic drugs: a comprehensive disproportionality analysis of the FDA adverse event reporting system. Front. Pharmacol.14, 1170039. https://doi.org/10.3389/fphar.2023.1170039 (2023).
doi: 10.3389/fphar.2023.1170039
pubmed: 37251345
pmcid: 10213327
Roden, D.M. Mechanisms and management of proarrhythmia. Am. J. Cardiol.82(4A), 49I–57I. https://doi.org/10.1016/s0002-9149(98)00472-x (1998).
doi: 10.1016/s0002-9149(98)00472-x
Levine, J. H., Morganroth, J. & Kadish, A. H. Mechanisms and risk factors for proarrhythmia with type Ia compared with ic antiarrhythmic drug therapy. Circulation. 80(4), 1063–1069. https://doi.org/10.1161/01.cir.80.4.1063 (1989).
doi: 10.1161/01.cir.80.4.1063
pubmed: 2676234
Herre, J. M. et al. Inefficacy and proarrhythmic effects of flecainide and encainide for sustained ventricular tachycardia and ventricular fibrillation. Ann. Intern. Med.113(9), 671–676. https://doi.org/10.7326/0003-4819-113-9-671 (1990).
doi: 10.7326/0003-4819-113-9-671
pubmed: 2121082
Julian, D. G. et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European myocardial infarct amiodarone trial investigators. Lancet349(9053), 667–674. https://doi.org/10.1016/s0140-6736(96)09145-3 (1997).
doi: 10.1016/s0140-6736(96)09145-3
pubmed: 9078197
Varró, A., Virág, L. & Papp, J. G. Comparison of the chronic and acute effects of amiodarone on the calcium and potassium currents in rabbit isolated cardiac myocytes. Br. J. Pharmacol.1176), 1181–1186. https://doi.org/10.1111/j.1476-5381.1996.tb16713.x (1996).
doi: 10.1111/j.1476-5381.1996.tb16713.x
pubmed: 8882613
pmcid: 1909794
Abi-Gerges, N. et al. hERG subunit composition determines differential drug sensitivity. Br. J. Pharmacol.164(2b), 419–432. https://doi.org/10.1111/j.1476-5381.2011.01378.x (2011).
doi: 10.1111/j.1476-5381.2011.01378.x
pubmed: 21449979
pmcid: 3188906
Orvos, P. et al. Evaluation of possible proarrhythmic potency: comparison of the Effect of Dofetilide, Cisapride, Sotalol, Terfenadine, and Verapamil on hERG and native IKr currents and on Cardiac Action potential. Toxicol. Sci.168(2), 365–380. https://doi.org/10.1093/toxsci/kfy299 (2019).
doi: 10.1093/toxsci/kfy299
pubmed: 30561737
Varro, A. et al. The role of the delayed rectifier component IKs in dog ventricular muscle and Purkinje fibre repolarization. J. Physiol.523(Pt 1), 67–81. https://doi.org/10.1111/j.1469-7793.2000.00067.x (2000).
doi: 10.1111/j.1469-7793.2000.00067.x
pubmed: 10675203
pmcid: 2269783
Jost, M. et al. Ionic mechanisms limiting cardiac repolarization reserve in humans compared to dogs. J. Physiol.591(17), 4189–4206. https://doi.org/10.1113/jphysiol.2013.261198 (2013).
doi: 10.1113/jphysiol.2013.261198
pubmed: 23878377
pmcid: 3779111
Varró, A. et al. Cardiac transmembrane ion channels and action potentials: cellular physiology and arrhythmogenic behavior. Physiol. Rev.101(3), 1083–1176. https://doi.org/10.1152/physrev.00024.2019 (2021).
doi: 10.1152/physrev.00024.2019
pubmed: 33118864
Vivek, S. N., Rakesh, K. & Agarwal, D. D. Rapid and environment friendly method for acid free iodination of industrially important organics using I2/NaClO3/CH3OH system. Res. J. Chem. Environ.26(12), 31–43 (2022).
doi: 10.25303/2612rjce031043
Dafei, M., Dongliang, L., Jin, W. & Ting, Z. Guangfei, P. Process for Rapidly Synthesizing Ioxynil (CN 110105243 A, 2019).
Xiaohong, C. et al. D-A-D bent-core Bota liquid crystal compounds. CN 106675574 A, (2017).
Rocha, B. C. O., Perecim, G. P. & Raminelli, C. Biomimetic iodofunctionalization of aromatic and heteroaromatic compounds catalyzed by Selenium Tetrachloride. SynOpen. 3, 142–147. https://doi.org/10.1055/s-0039-1690337 (2019).
doi: 10.1055/s-0039-1690337
Liu, D., Sanow, L. P. & Zhang, C. Mitsunobu reactions of aliphatic alcohols and bulky phenols. Tetrahedron Lett.55(19), 3090–3092. https://doi.org/10.1016/j.tetlet.2014.03.138 (2014).
doi: 10.1016/j.tetlet.2014.03.138
Lepore, S. D. & He, Y. Use of Sonication for the Coupling of Sterically Hindered substrates in the phenolic Mitsunobu Reaction. J. Org. Chem.68(21), 8261–8263. https://doi.org/10.1021/jo0345751 (2003).
doi: 10.1021/jo0345751
pubmed: 14535815
Hurd, C. D., Perletz, P. & Aryloxyacetones J. Am. Chem. Soc.68(1), 38–40 DOI: https://doi.org/10.1021/ja01205a012 (1946).
doi: 10.1021/ja01205a012
Patrice, S., Steven, W. J., Guy, W. W. & Daniel, C. E. Fungicides WO2005044008 A2, (2005).
Victor, B. R., Ronald, C. A., Jon, L. T., Tasneem, M. R. & Stephen, T. Substituted indule derivatives for pharmaceutical composition for treating respiratory diseases. WO2005019171 A1, (2005).
Patrick, D. A. et al. Synthesis and antiprotozoal activities of benzyl phenyl ether diamidine derivatives. Eur. J. Med. Chem.67, 310–324 (2013).
doi: 10.1016/j.ejmech.2013.06.033
pubmed: 23871911
Patel, S. et al. Identification of appropriate QTc formula in beagle dogs for nonclinical safety assessment. Regul. Toxicol. Pharmacol.89, 118–124. https://doi.org/10.1016/j.yrtph.2017.07.026 (2017).
doi: 10.1016/j.yrtph.2017.07.026
pubmed: 28751260
Gömöri, K. et al. Cardioprotective effect of Novel Matrix Metalloproteinase inhibitors. Int. J. Mol. Sci.21(19), 6990. https://doi.org/10.3390/ijms21196990 (2020).
doi: 10.3390/ijms21196990
pubmed: 32977437
pmcid: 7582346
Curtis, M. J. et al. The Lambeth conventions (II): guidelines for the study of animal and human ventricular and supraventricular arrhythmias. Pharmacol. Ther.139(2), 213–248. https://doi.org/10.1016/j.pharmthera.2013.04.008 (2013).
doi: 10.1016/j.pharmthera.2013.04.008
pubmed: 23588158
Jost, N. et al. Restricting excessive cardiac action potential and QT prolongation: a vital role for IKs in human ventricular muscle. Circulation112(10), 1392–1399. https://doi.org/10.1161/CIRCULATIONAHA.105.550111 (2005).
doi: 10.1161/CIRCULATIONAHA.105.550111
pubmed: 16129791
Kristóf, A. et al. Diclofenac prolongs repolarization in ventricular muscle with impaired repolarization reserve. PLoS One. 7(12). https://doi.org/10.1371/journal.pone.0053255 (2012). e53255.
Lengyel, C. et al. Pharmacological block of the slow component of the outward delayed rectifier current (I(Ks)) fails to lengthen rabbit ventricular muscle QT(c) and action potential duration. Br. J. Pharmacol.132(1), 101–110. https://doi.org/10.1038/sj.bjp.0703777 (2001).
doi: 10.1038/sj.bjp.0703777
pubmed: 11156566
pmcid: 1572535
Orvos, P. et al. Effects of Chelidonium majus extracts and major alkaloids on hERG potassium channels and on dog cardiac action potential - a safety approach. Fitoterapia100, 156–165. https://doi.org/10.1016/j.fitote.2014.11.023 (2015).
doi: 10.1016/j.fitote.2014.11.023
pubmed: 25481375
Kúsz, N. et al. Diterpenoids from Euphorbia dulcis with Potassium Ion Channel Inhibitory activity with Selective G Protein-Activated Inwardly Rectifying Ion Channel (GIRK) blocking effect. J. Nat. Prod.81(11), 2483–2492. https://doi.org/10.1021/acs.jnatprod.8b00500 (2018).
doi: 10.1021/acs.jnatprod.8b00500
pubmed: 30411614